S. 5043

S. 5043: A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People’s Republic of China or other foreign countries, to establish enhanced safeguards for import

Introduced Ted Budd (R) SENATE_BILL — 119th Congress
Plain English Summary

S. 5043 is a bill aimed at strengthening the Food and Drug Administration's (FDA) authority to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from China and other foreign countries. It seeks to establish enhanced safeguards to ensure that drugs entering the U.S. market meet safety and efficacy standards.

Positive Media Summary

Supporters of S. 5043 have praised the bill for its proactive approach to protecting public health and safety. They argue that by preventing the importation of unsafe drugs, the legislation will help ensure that American consumers have access to safe and effective medications. Advocates believe that this bill is a necessary step in combating the growing threat of counterfeit drugs in the global market.

Negative Media Summary

Critics of S. 5043 have raised concerns about potential trade implications and the impact on drug prices. Some argue that the bill could lead to increased regulatory burdens on legitimate drug importers, potentially resulting in shortages or higher costs for consumers. Additionally, there are fears that the focus on China may exacerbate tensions between the two countries.

Conflict of Interest Analysis Deep Analysis
2/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Health

The analysis of bill S. 5043, aimed at preventing the importation of counterfeit drugs, reveals no direct industry overlaps between the sponsor Ted Budd's top donor industries and the subject matter of the bill. The top donors primarily represent sectors such as automotive innovation, software, and health strategies, none of which have a direct financial interest in drug importation regulations. The lobbying activity in this policy area does not indicate significant influence from pharmaceutical or healthcare sectors that would typically be involved in drug importation issues. Therefore, the risk of conflicts of interest appears minimal, as the financial contributions do not align with the bill's objectives.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS AMERICAN COLLEGE OF EMERGENCY PHYSICIANS $498,299
TRUST FOR PUBLIC LAND THE TRUST FOR PUBLIC LAND $150,000
COLLIER COLLECTIVE, LLC MCCOLL STRATEGIES LLC $40,000
HART HEALTH STRATEGIES TIM YEHL, LLC $40,000
PANO AI PANO AI $40,000
ALLIANCE FOR AUTOMOTIVE INNOVATION TIM YEHL, LLC $30,000
BSA, THE SOFTWARE ALLIANCE TIM YEHL, LLC $20,000
PSEG SERVICES CORPORATION TIM YEHL, LLC $20,000
COUNTY OF NAPA PARAGON GOVERNMENT RELATIONS $15,000
LAKE COUNTY PARAGON GOVERNMENT RELATIONS $15,000
NEVADA COUNTY PARAGON GOVERNMENT RELATIONS $15,000
HUMBOLDT COUNTY PARAGON GOVERNMENT RELATIONS $15,000
NATIONAL ASSOCIATION OF COUNTY HUMAN SERVICES ADMINISTRATORS PARAGON GOVERNMENT RELATIONS $10,000
NATIONAL CHILD SUPPORT ENFORCEMENT ASSOCIATION PARAGON GOVERNMENT RELATIONS $10,000
CLARK COUNTY PARAGON GOVERNMENT RELATIONS undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us